| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e3b4f2ef8f062dcde3a2b7cd81748472
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d4f84f6c10c790aa3099ffe57c2d230b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-706 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-706
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 |
| filingDate |
2017-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f445a6343ad807853dcba21d6adbf6e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7e8a61025c18f9780f12814b191f6f1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94e44e178a058990fa4118c29ed46cb5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_587806f96d7f3d8260ffec0f72edc951
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_719b40eb832f46fd47f03e026f5d6316
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_217b4691abc40297bb993d71eb3c2f24 |
| publicationDate |
2019-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3478297-A1 |
| titleOfInvention |
Methods and pharmaceutical compositions for the treatment of cardiomyopathies |
| abstract |
The present invention relates to methods and pharmaceutical compositions for the treatment of cardiomyopathies. The inventors showed that the nicotinamide riboside kinase Nmrk2 gene involved in NAD+ biosynthetic pathway is strongly induced in the heart of the mouse models of dilated cardiomyopathy and that Nmrk2 is an AMPK and PPARĪ± responsive gene. They also showed that the NMRK enzymes substrate nicotinamide riboside supplementation in food markedly improves cardiac functions and reduces eccentric remodeling. The inventors demonstrated that both the NMRK1 and NMRK2 protein are expressed in the human healthy heart, that NMRK2 protein level is increased in human failing hearts as it is the case in mouse failing hearts in several models of heart failure and cardiomyopathies. In particular, the present invention relates to nicotinamide riboside for use in the treatment of cardiomyopathy in a human subject in need thereof. |
| priorityDate |
2016-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |